Gelofusin solution for infusions bottle 500 ml No. 10

Gelofusin solution for infusion is indicated for:

Composition

Active ingredients: succinylated gelatin (modified liquid gelatin), sodium chloride;

: 1000 ml of solution contain:

Electrolyte concentration:

Excipients: sodium hydroxide, water for injections.

Contraindication

Method of application

Before administration, the solution should be warmed to body temperature.

When administering Gelofusine by pressurized infusion (including using a cuff or infusion pump), all air must be removed from the container and administration system before administering the solution, as there is a risk of air embolism during infusion.

Application features

Pregnant women

It should be used during pregnancy only if the expected benefit to the mother outweighs the risk to the fetus.

Children

Experience with the use of Gelofusine in children is limited, therefore the drug should be used in this age group only after a careful benefit-risk assessment and with careful monitoring.

Drivers

There is no sufficient experience of the effect of treatment on the ability to drive vehicles or operate machinery.

Overdose

Overdose or too rapid administration of Gelofusine may lead to unintentional hypervolemia and circulatory overload, associated with subsequent impairment of cardiac and pulmonary function. Symptoms of circulatory overload include headache, dyspnea, and jugular venous congestion.

At the first signs of circulatory overload, the infusion should be stopped immediately. Treatment is symptomatic. Diuretics may be necessary.

Side effects

Interaction

Mixing Gelofusine with other drugs may lead to incompatibility. Gelofusine should not be administered simultaneously with fat emulsions.

Storage conditions

Store at a temperature not exceeding 25 °C. Do not freeze.

Keep out of reach of children.

Shelf life - 3 years.